Lakefront Biotherapeutics (LKFT) Total Current Liabilities (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Total Current Liabilities of $117.6 million for Q1 2026, down 74.43% year-over-year from $459.7 million in Q1 2025, and down 33.93% quarter-over-quarter from $177.9 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Total Current Liabilities (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Total Current Liabilities for 13 consecutive years, with $117.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 74.43% year-over-year to $117.6 million; the TTM figure through Mar 2026 stood at $117.6 million (down 74.43% YoY), while the FY2025 annual figure was $177.9 million, down 50.31% from the prior year.
- Total Current Liabilities slipped to $117.6 million in Q1 2026 per LKFT's latest filing, from $177.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $631.8 million in Q1 2022 and bottomed at $117.6 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $420.7 million across 5 years, with a median of $456.1 million in 2025.
- Annual changes were most pronounced in 2025 — Total Current Liabilities grew 11.1% — and 2026, when it plunged 74.43%.
- Lakefront Biotherapeutics' Total Current Liabilities stood at $533.1 million in 2022, then dropped by 13.58% to $460.7 million in 2023, then declined by 22.28% to $358.1 million in 2024, then tumbled by 50.31% to $177.9 million in 2025, then plunged by 33.93% to $117.6 million in 2026.
- Business Quant data shows LKFT's Total Current Liabilities at $117.6 million in Q1 2026, $177.9 million in Q4 2025, and $428.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 117.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 117.57 Mn |
| Dec 31, 2025 | 177.94 Mn |
| Sep 30, 2025 | 428.53 Mn |
| Jun 30, 2025 | 456.13 Mn |
| Mar 31, 2025 | 459.72 Mn |
| Dec 31, 2024 | 358.07 Mn |
| Sep 30, 2024 | 385.73 Mn |
| Mar 31, 2024 | 415.22 Mn |
| Dec 31, 2023 | 460.74 Mn |
| Sep 30, 2023 | 483.37 Mn |
| Mar 31, 2023 | 561.25 Mn |
| Dec 31, 2022 | 533.12 Mn |
| Mar 31, 2022 | 631.76 Mn |
| Dec 31, 2021 | 648.03 Mn |
| Jun 30, 2021 | 694.85 Mn |
| Dec 31, 2020 | 757.43 Mn |
| Jun 30, 2020 | 681.29 Mn |
| Mar 31, 2020 | 687.34 Mn |
| Dec 31, 2019 | 632.91 Mn |
| Sep 30, 2019 | 702.47 Mn |